Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2579704 | Thérapie | 2006 | 4 Pages |
Abstract
The purpose of this paper is to examine the eventual benefits of treatment with calcium channel blockers in post-myocardial infarction, through an overview of main placebo-controlled trials that have been conducted to test this therapeutic in acute coronary syndromes. It appears obvious that the vast majority of these trials was conducted in the pre-reperfusion era and failed to demonstrate a reduction in mortality. To conclude, the superiority of a therapy with calcium antagonists over a placebo in the management of post-myocardial infarction remains unknown. In contrast, adverse effects associated with the prescription of calcium antagonists are well known.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
Pierre-Vladimir Ennezat, Jean-Luc Auffray, Julie Darchis, Maxime Ronsselle, Xavier Gonin, Jean-Marc Aubert, Jean-Jacques Bauchart, Christophe Bauters, Eric Van Belle, Philippe Asseman,